Improved work productivity, safety, and quality of life with pegylated (40KDA) interferon alfa-2a (Pegasys™) therapy in the treatment of chronic hepatitis C.

被引：0
|
作者：
Perrillo, RP
Thuluvath, PJ
Rothstein, K
Alam, I
Palmer, M
Gordon, S
Pappas, SC
Wynohradnyk, L
机构：
[1] Alton Ochsner Med Fdn & Ochsner Clin, New Orleans, LA 70121 USA
[2] Johns Hopkins Hosp, Baltimore, MD 21287 USA
[3] Albert Einstein Med Ctr, Philadelphia, PA 19141 USA
[4] Clin Res Ctr, Austin, TX USA
[5] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA
[6] Roche Lab Inc, Nutley, NJ USA
来源：
HEPATOLOGY | 2000年 / 32卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
809
引用
收藏
页码：362A / 362A
页数：1
相关论文
共 50 条
  • [1] Therapy with pegylated (40kDa) interferon alfa-2a (Pegasys™) significantly enhances quality of life compared with standard interferon alfa-2za (roferon-A®) in patients with chronic hepatitis C.
    Rasenack, J
    Zeuzem, S
    Feinman, SV
    Heathcote, EJ
    Manns, M
    Yoshida, E
    Swain, MG
    Gane, E
    Diago, M
    Lin, A
    Green, J
    Revicki, D
    [J]. HEPATOLOGY, 2000, 32 (04) : 307A - 307A
  • [2] Characterization of pegylated (40kDa) interferon alfa-2A (Pegasys™) in the elderly.
    Martin, NE
    Modi, MW
    Reddy, KR
    [J]. HEPATOLOGY, 2000, 32 (04) : 348A - 348A
  • [3] Enhanced efficacy of pegylated (40kDa) interferon alfa-2A (Pegasys™) compared with interferon alfa-2A (Roferon-A™) for chronic hepatitis C in Blacks.
    Shiffman, ML
    Fromm, H
    Mills, P
    Moonka, DK
    Fried, MW
    Berg, C
    Sherman, M
    Smith, C
    Marsano, L
    Reddy, KR
    Brunda, MJ
    DePamphilis, J
    [J]. HEPATOLOGY, 2000, 32 (04) : 348A - 348A
  • [4] Pegylated (40KDA) interferon ALFA-2A (Pegasys™) is unaffected by renal impairment.
    Martin, P
    Mitra, S
    Farrington, K
    Martin, NE
    Modi, MW
    [J]. HEPATOLOGY, 2000, 32 (04) : 370A - 370A
  • [5] Clearance of pegylated (40KDA) interferon alfa-2a (Pegasys™) is primarily hepatic.
    Modi, MW
    Fulton, JS
    Buckmann, DK
    Wright, TL
    Moore, DJ
    [J]. HEPATOLOGY, 2000, 32 (04) : 371A - 371A
  • [6] The pharmacokinetic behavior of pegylated (40kDa) interferon alfa-2a (PEGASYS™) in chronic hepatitis C patients after multiple dosing.
    Modi, MW
    Fried, M
    Reindollar, RW
    Rustgi, VR
    Kenny, R
    Wright, TL
    Gibas, A
    Martin, NE
    [J]. HEPATOLOGY, 2000, 32 (04) : 394A - 394A
  • [7] Pegylated (40kDa) interferon alfa-2a (pegasys™) is superior to interferon alfa-2a (roferon-A®) in improving posttreatment histologic outcome in chronic hepatitis C patients 1584.
    Heathcote, EJ
    Balart, LA
    Shiffman, ML
    Pockros, PJ
    Lee, SS
    Reddy, KR
    Minuk, YG
    Bain, V
    Sherman, M
    Wright, TL
    Reindollar, RW
    Brunda, MJ
    [J]. HEPATOLOGY, 2000, 32 (04) : 223A - 223A
  • [8] Rapid viral response to treatment with pegylated (40KDA) interferon ALFA-2A (PEGASYS™) is strongly predictive of a sustained virologic response in patients with chronic hepatitis C (CHC).
    Neumann, AU
    Zeuzem, S
    Brunda, MJ
    Hoffman, JH
    [J]. HEPATOLOGY, 2000, 32 (04) : 318A - 318A
  • [9] Superior virologic response in genotype 4 chronic hepatitis C patients treated with pegylated (40kDa) interferon alfa-2A (Pegasys™) compared with standard interferon.
    Sherman, M
    Dusheiko, GM
    Haeussinger, D
    Marinos, G
    Munoz-Espinoza, L
    Salmeron, J
    DePamphilis, J
    Brunda, MJ
    [J]. HEPATOLOGY, 2000, 32 (04) : 348A - 348A
  • [10] Treatment of haemodialysis patients with chronic hepatitis C using pegylated interferon alfa-2A (Pegasys)
    Sim, N. Zulkarnain
    Chiu, A.
    Wong, H. S.
    [J]. NEPHROLOGY, 2008, 13 : A53 - A53
12345